400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
ChiCTR2600123578
尚未开始
/
/
/
2026-04-28
/
/
近视
角膜塑形镜联合低浓度阿托品在青少年近视防控中的疗效及影响因素分析
角膜塑形镜联合低剂量硫酸阿托品眼用凝胶对小儿近视的疗效及影响因素分析
评估角膜塑形术(OK镜)联合0.01%阿托品在控制青少年近视进展中的疗效,并明确其影响因素。
随机平行对照
其它
由研究者采用计算机生成的随机数字表进行随机化,采用简单随机数字确保分配隐藏。
本研究严格遵循盲法原则:所有参与者均不知晓其分组情况及所接受的治疗。由于干预措施的性质,尽管负责护士知晓实际护理分配情况,但严格保密,未参与结果评估;所有指标数据均由完全不知晓分组情况的研究助理收集和评估,从而确保评估过程的客观性。这种盲法设置从干预开始一直持续到所有数据的收集和分析完成。
项目自筹
/
103
/
2026-04-01
2028-04-01
/
Adolescents aged 8–12 years with myopia diagnosed according to established ophthalmologic criteria were eligible if they had a spherical equivalent between −1.0 and −6.0 D, astigmatism <1.0 D and less than half of the spherical equivalent, best-corrected visual acuity (LogMAR) >= 0.1, intraocular pressure <= 21 mmHg, no history of ocular disease, ocular surgery, or trauma, no contraindications to OK lens wear, and written informed consent obtained from the participants and their guardians. Adolescents aged 8–12 years with myopia diagnosed according to established ophthalmologic criteria were eligible if they had a spherical equivalent between −1.0 and −6.0 D, astigmatism <1.0 D and less than half of the spherical equivalent, best-corrected visual acuity (LogMAR) >= 0.1, intraocular pressure <= 21 mmHg, no history of ocular disease, ocular surgery, or trauma, no contraindications to OK lens wear, and written informed consent obtained from the participants and their guardians.;
请登录查看如果参与者对阿托品或其他与研究相关的药物过敏或不耐受、之前使用过隐形眼镜或阿托品来控制近视、无法遵守预定的随访检查、有圆锥角膜家族史、眼部或全身性影响视力或近视进展的疾病、在研究期间使用药物或其他可能影响屈光结果的干预措施,或者在研究期间参与其他临床研究,则会被排除在外。;
请登录查看郑州大学第一附属医院
/
精准药物2026-05-18
小药说药2026-05-18
干细胞与外泌体2026-05-18
药明康德2026-05-18
云顶新耀2026-05-18
识林2026-05-18
CCMTV2026-05-17
干细胞与外泌体2026-05-17
生物技术小编2026-05-17
良医汇肿瘤资讯2026-05-16